HBM HOLDINGS-B (02142): HBM7575, a new drug for the treatment of atopic dermatitis, has received approval for clinical trial application from the NMPA.
Boehringer Ingelheim Pharmaceuticals Ltd. (02142) announced that the new drug clinical trial application (IND) for the long-acting bispecific antibody HBM7575 (also known as SKB575) targeting thymic stromal lymphopoietin (TSLP) for the treatment of atopic dermatitis has been approved by the China National Medical Products Administration (NMPA).
HBM HOLDINGS-B (02142) announced that the new drug clinical trial (IND) application for the targeted thymic stromal lymphopoietin (TSLP) and a undisclosed target long-acting bispecific antibody HBM7575 (also known as SKB575) for the treatment of atopic dermatitis has been approved by the China National Medical Products Administration (NMPA).
Related Articles
On March 9, MNSO(09896) spent 1.73 million Hong Kong dollars to repurchase 52,600 shares.
Shenwan Hongyuan Group (06806): "23th C2 application" will be redeemed and delisted on March 6th.
On March 9, Le Saunda (00738) spent HK$58,000 to repurchase 200,000 shares.
On March 9, MNSO(09896) spent 1.73 million Hong Kong dollars to repurchase 52,600 shares.
Shenwan Hongyuan Group (06806): "23th C2 application" will be redeemed and delisted on March 6th.
On March 9, Le Saunda (00738) spent HK$58,000 to repurchase 200,000 shares.
RECOMMEND
